Ona Therapeutics’s oversubscribed $86.6M Series B in June 2026 is European biotech at its most fundable: differentiated, validated science aimed at a hard clinical problem.

The problem this startup is attacking

Treatment-resistant cancers evade existing therapies. Ona develops first-in-class antibody-drug conjugates (ADCs) — targeted payloads designed to kill cancer cells that current drugs can’t reach.

Why this is a live problem now

• ADCs are one of oncology’s hottest modalities.
• Treatment resistance is a major unmet need.
• The reopening exit market improves European biotech funding appetite.

Competitive map

• Global ADC developers and big-pharma oncology pipelines.
• Other European clinical-stage biotechs.

Market signal (the number to remember)

• Oversubscribed $86.6M Series B — strong demand for a Barcelona biotech signals investor appetite for validated, differentiated oncology science.

Practical takeaway (operator + investor)

Ona shows European biotech can raise robustly on first-in-class science and clear clinical rationale. Founders should lead with mechanism and preclinical/clinical data; investors should keep European life sciences in the mix.

Sources

1. Startuprise (Ona Therapeutics $86.6M Series B): https://startuprise.co.uk/top-funding-wrap-of-the-week-01-june-05-june-2026/